Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructurePatricia Mary Davidson, DM Rees, TA Brighton, Joseph Enis, J McCrohon, Doug Elliott, Jill Cockburn, Glenn Paull, John Daly
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Coronary heart disease and atrial fibrillation: the Framingham Study
10.1016/0002-8703(83)90208-9 · 1983
10.1016/s0735-1097(01)01586-8
10.1016/s0735-1097(01)01586-8 · 2001
Atrial fibrillation: The newest frontier in arryhthmia management
10.1111/j.0889-7204.2002.01450.x · 2002
Warfarin versus aspirin for prevention of thromboembolism in artial fibrillation: SPAF II study
1994
Non-valvular atrial fibrillation and stroke prevention [Position Statement]
10.5694/j.1326-5377.2001.tb143246.x · 2001
Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials
10.1016/s0735-1097(98)00297-6 · 1998
Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice
10.1136/bmj.313.7071.1534 · 1996
Mortality in an insured population with atrial fibrillation
10.1001/jama.1981.03310400022019 · 1981
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study
10.1161/01.str.22.8.983 · 1991
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study
10.1161/01.cir.98.10.946 · 1998
Preventing stroke in patients with atrial fibrillation
10.1001/jama.281.19.1830 · 1999
Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention
10.7326/0003-4819-131-9-199911020-00010 · 1999
Managing warfarin therapy in the community
10.18773/austprescr.2001.096 · 2001
From rebellious palpitations to the discovery of auricular fibrillation: contributions of Meccans, Lewis and Einthoven
10.1016/0002-9149(94)90013-2 · 1994
Atrial fibrillation: treatment rationale and clinical utility of nonpharmacologic therapies
10.1097/00044067-200102000-00014 · 2001
Medical Progress: Atrial Fibrillation
10.1056/nejm200104053441407 · 2001
Cardioversion guided by transesophageal echocardiography: the ACUTE pilot study: a randomized, controlled trial
10.7326/0003-4819-126-3-199702010-00004 · 1997
Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast
10.1016/s0033-0620(96)80041-7 · 1996
Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi
10.1056/nejm199303183281102 · 1993
Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram
10.1016/s0002-9149(96)00828-4 · 1997
Echocardiographic predictors of stroke in patients with atrial fibrillation
10.1001/archinte.158.12.1316 · 1998
relationship between prothombin activation fragment F1.2 and international normalised ratio in patients with atrial fibrillation
10.1161/01.str.28.6.1101 · 1997
C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation
10.2143/ac.56.6.2005701 · 2001
D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis
10.1016/s0002-8703(96)90278-1 · 1996
Hypercoaguability and hemodynamic abnormalities in atrial fibrillation (comment)
10.1136/hrt.77.5.395 · 1997
relationship between prothombin activation fragment F1.2 and International Normalised Ratio in Patients with Atrial Fibrillation
10.1161/01.str.28.6.1101 · 1997
Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation
10.1136/hrt.77.5.407 · 1997
Design of a multicenter randomized trial for the stroke prevention in atrial fibrillation study
10.1161/01.str.21.4.538 · 1990
Silent cerebral infarction in patients with nonrheumatic atrial fibrillation
10.1161/01.cir.92.8.2178 · 1995
Atrial fibrillation and dementia in a population-based study: The Rotterdam Study
10.1161/01.str.28.2.316 · 1997
Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study
10.1161/01.str.28.5.957 · 1997
Rhythm or rate control in atrial fibrillation — pharmacological intervention in atrial fibrillation (PIAF): a randomised trial
10.1016/s0140-6736(00)03230-x · 2000
Atrial fibrillation follow-up investigation of rhythm management — the AFFIRM study design
10.1016/s0002-9149(97)00082-9 · 1997
Early recurrence of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria?
10.1016/s0735-1097(97)00455-5 · 1998
Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation
10.1016/0002-8703(95)90405-0 · 1995
Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans
10.1161/01.cir.101.10.1145 · 2000
Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis
10.1161/01.cir.101.10.1138 · 2000
Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation
10.1111/j.1540-8167.1999.tb00296.x · 1999
Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter-defibrillator
10.1161/01.cir.101.8.878 · 2000
The closed heart MAZE: a nonbypass surgical technique
10.1016/s0003-4975(99)00268-4 · 1999
Heparin and low molecular heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety
10.1378/chest.119.1_suppl.64s · doi-reference
Warfarin, antiplatelet drugs and their interactions
10.18773/austprescr.2002.073 · doi-reference
Changing physician performance: a systematic review of the effect of continuing medical education strategies
10.1001/jama.1995.03530090032018 · doi-reference
Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries
10.2105/ajph.88.3.395 · doi-reference
Antithrombotic therapy in atrial fibrillation
10.1378/chest.114.5_supplement.579s · doi-reference
Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation
10.1001/archinte.162.5.541 · doi-reference
Atrial fibrillation and cognitive disorders in older people
10.1111/j.1532-5415.2000.tb04695.x · doi-reference
A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial
10.1001/jama.281.2.145 · doi-reference
Perioperative management of the chronically anticoagulated patient
10.1023/a:1012746729537 · doi-reference
An analysis of the lowest dose of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
10.1056/nejm199608223350802 · doi-reference
A randomized clinical trial of outpatient comprehensive geriatric assessment coupled with an intervention to increase adherence to recommendations
10.1111/j.1532-5415.1999.tb02988.x · doi-reference
Warfarin therapy for an octogenarian who has atrial fibrillation
10.7326/0003-4819-134-6-200103200-00011 · doi-reference
Bleeding during antithrombotic therapy in patients with atrial fibrillation
10.1001/archinte.1996.00440040081009 · doi-reference
Stroke prevention in patients with non-valvular atrial fibrillation: a current community perspective
10.1016/s0967-5868(97)90099-0 · doi-reference
Effectiveness of anticoagulation among patients discharged from hospital on warfarin
10.5694/j.1326-5377.1998.tb140246.x · doi-reference
Warfarin use among ambulatory patient with nonvalvular atrial fibrillation. The anticoagulantion and risk factors in atrial fibrillation (ATRIA) study
10.7326/0003-4819-131-12-199912210-00004 · doi-reference
Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice?
10.1001/archinte.1994.00420170093009 · doi-reference
Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
10.1016/s0140-6736(97)01180-x · doi-reference
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials
10.1001/archinte.1994.00420130036007 · doi-reference
A systematic review of randomized trials of disease management programs in heart failure
10.1016/s0002-9343(00)00743-9 · doi-reference
Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin
10.1001/jama.279.16.1273 · doi-reference
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
10.1001/archinte.158.14.1513 · doi-reference
Adjusted-dose warfarin versus low intensity, fixed dose, warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trials
10.1016/s0140-6736(96)03487-3 · doi-reference
Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
10.1016/0140-6736(93)92358-z · doi-reference
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: the Veterans Affairs Cooperative Study
10.1056/nejm199211123272002 · doi-reference
Canadian Atrial Fibrillation Anticoagulation (CAFA) study
10.1016/0735-1097(91)90585-w · doi-reference
The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation
10.1056/nejm199011293232201 · doi-reference
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study
10.1016/s0140-6736(89)91200-2 · doi-reference